The perturbation of apoptosis and mitosis by drugs and xenobiotics

Pharmacology and Therapeutics

Volumn 82, Issue 1, 1999, Pages 63-70

  Hasmall, Susan C ^a   Roberts, Ruth A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Nongenotoxic carcinogenesis; Peroxisome proliferators; Phenobarbitone; S phase; Species differences

Indexed keywords

BARBITURIC ACID DERIVATIVE; BEZAFIBRATE; CARCINOGEN; CYPROTERONE ACETATE; DRUG; FENOFIBRATE; FIBRIC ACID DERIVATIVE; NAFENOPIN; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOBARBITAL; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; CELL CYCLE S PHASE; HEPATOMEGALY; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SPECIES DIFFERENCE;

ANIMALS; APOPTOSIS; CARCINOGENS; HUMANS; LIVER NEOPLASMS; MICE; MITOSIS; PEROXISOME PROLIFERATORS; PHARMACEUTICAL PREPARATIONS; RATS; RISK ASSESSMENT; SPECIES SPECIFICITY; XENOBIOTICS;

EID: 0033051348     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00058-8     Document Type: Review

References (57)

1. Ashby J., Brady A., Elcombe C.R., Elliot B.M., Ishmael J., Odum J., Tugwood J.D., Kettle S., Purchase I.F.H. Mechanistically-based human hazard assessment of peroxisome-proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13:1994;S1-S117.
2. Bains S.K., Gardiner S.M., Manweiler K., Gillett D., Gibson G.G. Immunocytochemical study on the contribution of hypolipidaemic-induced cytochrome P452 to the metabolism of lauric acid. Biochem. Pharmacol. 34:1985;3221-3229.
3. Bayly A.C., Roberts R.A., Dive C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator, nafenopin. J. Cell Biol. 125:1994;197-203.
4. Bentley P., Calder I., Elcombe C., Grasso P., Wiegand H.G., Stringer D.A. Hepatic Peroxisome Proliferation. 1992;Monograph 17, ECETOC, Brussels.
5. Bentley P., Calder I., Elcombe E., Grasso P., Stringer D., Wiegand H.J. Hepatic peroxisome proliferation in rodents and its significance to humans. Food Chem. Toxicol. 31:1993;857-907.
6. Berman J.S., Hiley C.R., Wilson A.C. Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on live size, blood flow and DNA content in the rat. Br. J. Pharmacol. 78:1983;533-541.
7. Bojes H.K., Germolec D.R., Simeonova P., Bruccoleri A., Schoonhoven R., Luster M.I., Thurman R.G. Antibodies to tumour necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. Carcinogenesis. 18:1997;669-674.
8. Bursch B., Lauer B., Timmerman-Trosiener I., Barthel G., Schuppler J., Schulte-Hermann R. Controlled death (apoptosis) of normal and preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis. 5:1984;453-458.
9. Bursch W., Dusterberg B., Schulte-Hermann R. Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. Arch. Toxicol. 59:1986;221-227.
10. Chevalier S., Roberts R.A. Perturbation of hepatocyte growth control by nongenotoxic hepatocarcinogens. Onc. Rep. 5:1998;1319-1327.
11. Chinnaiyan A.M., Tepper C.G., Seldin M.F., O'Rourke K., Kischkel F.C., Hellbardt S., Krammer P.H., Peter M.E., Dixit V.M. FADD/MORT1 is a common mediator of CD95(Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 271:1996;4961-4965.
12. Columbano A., Ledda-Columbano G.M., Ennas M.G., Curto M., Chelo A., Pani P. Cell proliferation and promotion of rat liver carcinogenesis. different effects of hepatic regeneration and mitogen induced hyperplasia on the development of enzyme altered foci Carcinogenesis. 11:1990;771-776.
13. Columbano A., Endoh T., Denda A., Noguchi O., Nakae D., Hasegawa K., Ledda-Columbano G.M., Zedda A.I., Konishi Y. Effects of cell proliferation and cell death (apoptosis and necrosis) on the early stages of rat hepatocarcinogenesis. Carcinogenesis. 17:1996;395-400.
14. Dive C., Evans C.A., Whetton A.D. Induction of apoptosis - new targets for cancer chemotherapy. Semin. Cancer Biol. 3:1992;417-427.
15. Eacho P.I., Foxworthy P.S., Dillard R.D., Whitesitt C.A., Herron D.K., Marshall W.S. Hepatic peroxisomal changes induced by tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol. Appl. Pharmacol. 83:1986;430-437.
16. Edwards A.M., Lucas C.M. Phenobarbital and some other live tumor promoters stimulate DNA synthesis in cultured rat hepatocytes. Biochem. Biophys. Res. Commun. 131:1985;103-108.
17. Elcombe C.R., Mitchell A. Peroxisome proliferation due to di(2-ethyl) phthalate. species differences and possible mechanisms Environ. Health Perspect. 70:1986;211-219.
18. Evan G.I., Brown L., Whyte M., Harrington E. Apoptosis and the cell cycle. Curr. Opin. Cell Biol. 7:1995;825-834.
19. Foxworthy P.S., White S.L., Hoover D.M., Eacho P.I. Effects of ciprofibrate, bezafibrate and LY171883 on peroxisomal beta-oxidation in cultured rat, dog and rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 104:1990;386-394.
20. Gerbracht U., Bursch W., Kraus P., Putz B., Reinacher M., Timmerman-Trosiener I., Schulte-Hermann R. Effects of the hypolipidaemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis. 11:1990;617-624.
21. Green S. The search for the molecular mechanisms of non-genotoxic carcinogenesis. Mutat. Res. 248:1991;371-374.
22. Gupta C., Hattori A., Betschart J.M., Virji M.A., Shinozuka H. Modulation of epidermal growth factor receptors in rat hepatocytes by two liver tumor-promoting regimes, a choline deficient diet and a phenobarbital diet. Cancer Res. 48:1988;1162-1166.
23. Hanefeld M., Hemmer C., Kadner E. Relationship between morphological changes and lipid lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis. 46:1983;239-246.
24. Heller R.A., Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J. Cell Biol. 126:1994;5-9.
25. Hertz R., Bishara-Shieban J., Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. J. Biol. Chem. 270:1995;13470-13475.
26. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell. 88:1997;347-354.
27. James N.H., Roberts R.A. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than with suppression of apoptosis. Carcinogenesis. 17:1996;1623-1632.
28. Kuenstle G., Leist M., Uhlig S., Revesz L., Feifel R., MacKenzie A., Wendel A. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNFα Immunol. Lett. 55:1997;5-10.
29. Lake B.G. Mechanisms of hepatocarcinogenicity of peroxisomes-proliferating drugs and chemicals. Annu. Rev. Pharmacol. Toxicol. 35:1995;483-507.
30. Lake B.G., Evans J.G., Gray T.J.B., Korosi S.A., North C.J. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, syrian hamster, guinea pig and marmoset. Toxicol. Appl. Pharmacol. 99:1989;148-160.
31. Lee S.S.-T., Pineau T., Drago J., Lee E.J., Owens J.O., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotrophic effects of peroxisome proliferators. Mol. Cell. Biol. 15:1995;3012-3022.
32. Liu Z., Hsu H., Goeddel D., Karin M. Dissection of TNF receptor 1 effector functions. JNK activation is not linked to apoptosis while NF-kappa B activation prevents cell death Cell. 87:1996;565-576.
33. Makowska J.M., Bonner F.W., Gibson G.G. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset. Arch. Toxicol. 65:1991;106-113.
34. Marzi I., Cowper K., Takei Y., Lindert K., Lemasters J.J., Thurman R.G. Methyl palmitate prevents Kupffer cell activation and improves survival after orthotopic liver transplantation in the rat. Transpl. Int. 4:1991;215-220.
35. Meikrantz W., Schlegel R. Apoptosis and the cell cycle. J. Cell Biochem. 58:1995;160-174.
36. Moody D.E., Rao M.S., Reddy J.K. Mitogenic effect in mouse liver induced by a hypolipidaemic drug, nafenopin. Virchows Arch. Pathol. 323:1977;291-296.
37. Moody D.E., Reddy J.K., Lake B.G., Popp J.A., Reese D.H. Peroxisome proliferation and non-genotoxic carcinogenesis. commentary on a symposium Fund. Appl. Toxicol. 6:1991;233-248.
38. Myers K.A., Lambe K.G., Aldridge T.C., Macdonald N., Tugwood J.D. Amino acid residues in both the DNA-binding and ligand-binding domains influence the transcriptional activity of the human peroxisome proliferator-activated receptor alpha. Biochem. Biophys. Res. Commun. 239:1997;522-526.
39. Ni R., Tomita Y., Matsuda K., Ichihara A., Ishimura K., Ogasawara J., Nagata S. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res. 215:1994;332-337.
40. Oberhammer F.A., Roberts R.A. Apoptosis. a widespread process involved in liver adaptation and carcinogenesis Arias I.M., Boyer J.L., Fausto N., Jakoby W.B., Schachter D.A., Shafritz D.A. The Liver. Biology and Pathobiology:1994;1547-1556 Raven Press, Ltd, New York.
41. Oberhammer F., Bursch W., Parzefall W., Breit P., Erber E., Stadler M., Schulte-Hermann R. Effect of transforming growth factor β on cell death of cultured rat hepatocytes. Cancer Res. 51:1991;2478-2485.
42. Periano C., Fry R.J.M., Staffeldt E., Christopher J.P. Comparative enhancing effects of phenobarbital, amobarbital, diphenylhydrantoin amd dichlorodiphenyltrichloroethane on 2-acetylaminofluorene-induced hepatic tumourigenesis in the rat. Cancer Res. 35:1975;2884-2890.
43. Price R.J., Evans J.G., Lake B.G. Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and syrian hamster. Fund. Chem. Toxicol. 30:1992;937-944.
44. Raffray M., Cohen G.M. Apoptosis and necrosis in toxicology. a continuum or distinct modes of cell death? Pharmacol. Ther. 75:1997;153-177.
45. Reddy J.K., Rao M.S., Azarnoff D.L., Sell S. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator Wy-14,643 in rat and mouse liver. Cancer Res. 39:1979;152-160.
46. Reddy J.K., Azarnoff D.L., Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature. 283:1980;397-398.
47. Roberts R.A. TUNEL - morituri te salutant (Commentary). Hum. Exp. Toxicol. 15:1995;457-458.
48. Roberts R.A. Non-genotoxic hepatocarcinogenesis. suppression of apoptosis by peroxisome proliferators Ann. NY Acad. Sci. 804:1996;588-602.
49. Roberts R.A., Soames A.R., Gill J.H., James N.H., Wheeldon E.B. Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different discrete hepatocyte populations. Carcinogenesis. 16:1995;1693-1698.
50. Roberts R.A., James N.H., Woodyatt N., Macdonald N., Tugwood J. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPARα). Carcinogenesis. 19:1998;43-48.
51. Rolfe M., James N.H., Roberts R.A. Tumour necrosis factor alpha (TNF-alpha) suppresses apoptosis and induces S-phase in rodent hepatocytes. a mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis. 18:1997;2277-2280.
52. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;905-925.
53. Schulte-Hermann R., Hoffann V., Parzefall W., Kallenbach M., Gerhardt A., Schuppler J. Adaptive responses of the liver to the gestagen and anti-androgen cyproterone acetate and other inducers. II. Induction of growth. Chem. Biol. Interact. 31:1980;287-300.
54. Tugwood J.D., Holden P.R., James N.H., Prince R.A., Roberts R.A. Isolation and characterisation of a functional peroxisome proliferator activated receptor alpha from guinea pig. Arch. Toxicol. 72:1998;169-177.
55. Watanabe T., Horie S., Yamada J., Isaji M., Nishigaki T., Naito J., Suga T. Species differences in the effects of bezafibrate, a hypolipidaemic agent, on hepatic peroxisome associated enzymes. Biochem. Pharmacol. 38:1989;430-437.
56. Wheeldon E., Williams S., Soames A., James N., Roberts R.A. Quantitation of apoptotic bodies by In Situ End Labelling (ISEL). correlation with morphology Toxicol. Pathol. 23:1995;410-415.
57. Williams G.M., Perrone C. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Ann. NY Acad. Sci. 804:1996;554-572.